Natasha Theriault is developing a bacteriophage-based vaccine platform which can be rapidly adapted against newly-emerging pathogens and safely distributed in locations regardless of cold-supply chain infrastructure.
Login or Register
You need to be logged in to use this feature.
Further Activities to have a look at